Search Results
Your search for The ASCO Post matches 17122 pages
Showing 1551 - 1600FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers
The U.S. Food and Drug Administration (FDA) announced a new voluntary pilot program to help physicians select safe and effective cancer treatments, with guidance on in vitro companion diagnostic tests to determine which corresponding oncology drugs may provide the most benefit for their patients....
Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin...
Adagrasib Shows Activity in Patients With KRAS G12C–Mutated NSCLC and Untreated Brain Metastases
The KRAS G12C inhibitor adagrasib may be effective at suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to a new study published by Negrao et al in the Journal of Clinical Oncology....
Patients With Refractory Metastatic Colorectal Cancer May Experience Survival Benefits With Fruquintinib
Targeted therapy with fruquintinib may improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer, according to a novel study published by Dasari et al in The Lancet. Background According to the American Cancer Society, colorectal cancer is the...
Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors
Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeting. Background Aromatase inhibitors are designed to block the activity of the aromatase enzyme,...
Older Breast Cancer Survivors May Experience Accelerated Aging, Worse Functional Outcomes Following Chemotherapy
Investigators have found that older breast cancer survivors—particularly those exposed to chemotherapy—may experience greater epigenetic aging and poorer outcomes than those without a history of cancer, according to a new study published by Rentscher et al in Cancer. Background Epigenetic aging...
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed or Refractory DLBCL
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma,...
Impact of Historic Redlining Practices on Cancer Screening Rates
Although redlining was outlawed more than 50 years ago, individuals who currently live in historically redlined areas may be less likely to be screened for breast cancer, colorectal cancer, and cervical cancer than individuals who live in areas not associated with redlining practices, according to...
Study Evaluates Clinical Utility of Novel Liquid Biopsy-Breast Cancer Methylation Prototype Assay
A novel, automated liquid biopsy test—the Liquid Biopsy for Breast Cancer Methylation assay—may be effective at predicting early disease progression and potential survival outcomes in patients with metastatic breast cancer after as little as 1 month of treatment, according to a study published by...
Research Sheds Light on the Evolution of Precursor Conditions to Multiple Myeloma
Researchers have shared novel insights into the evolution of multiple myeloma from precursor disease, which may help physicians better identify patients whose disease is likely to progress as well as develop new interventions, according to a recent study published by Dang et al in Cancer Cell. How...
Alectinib May Be More Effective When Taken With Larger Meals in Some Patients With NSCLC
Researchers have found that when the small molecule kinase inhibitor alectinib was taken in combination with a fuller breakfast or lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast in patients with non–small cell lung cancer (NSCLC), according...
Mortality Rates From Second Cancers in Hispanic and Non-Hispanic Black Breast Cancer Survivors
Hispanic and non-Hispanic Black breast cancer survivors may experience higher rates of mortality after being diagnosed with a second primary cancer than breast cancer survivors of other ethnic and racial groups, according to a new study published by Deng et al in the Journal of the National Cancer...
Impact of MCCPDC Prices of Generic Oncology Drugs on Medicare Beneficiaries
Medicare beneficiaries could save between $228.1 million and $2.15 billion per year if insurers operating the U.S. government's Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company (MCCPDC), according to a new study...
Preoperative Stereotactic Radiosurgery May Help Patients With Metastatic Brain Tumors Reduce the Risk of Disease Progression and Adverse Effects
Researchers have found that preoperative stereotactic radiosurgery is associated with low rates of tumor recurrence, adverse radiation effects, and meningeal disease in patients with metastatic brain tumors, according to a novel study published by Prabhu et al in JAMA Oncology. Background As...
Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding
Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequently in other racial and ethnic groups, according to a new study published by Haghighat et al in the...
Personalized mRNA Vaccines May Transform the Treatment of Melanoma
The rates of survival and disease recurrence improved significantly when a personalized mRNA vaccine tailored to the patients’ tumor genetics was coupled with immunotherapy in those who had undergone surgery for high-risk melanoma, according to novel findings presented by Khattak et al at the 2023...
Exposure to Ultraviolet Radiation May Propel Transformation of BPDCN Cells to Leukemia in the Skin
For some precancerous cells, traveling from the bone marrow to the skin can trigger genetic transformations that can result in leukemia, according to a novel study published by Griffin et al in Nature. The new findings may have shed light on what researchers have termed the “genetic travelogue” of...
Clifford A. Hudis, MD, on ASCO 2023 Perspectives: The Power of Connecting and Collaborating
Clifford A. Hudis, MD, ASCO Chief Executive Officer, talks about extending the reach and impact of ASCO by partnering with patients who play a key role in advancing science through clinical trial participation. With near-record numbers of registered attendees, the 2023 Annual Meeting fostered new...
Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide
Reid Merryman, MD, of Dana-Farber Cancer Institute, discusses his findings on the regimen of epcoritamab plus rituximab and lenalidomide for patients with high-risk follicular lymphoma. Regardless of whether their disease progressed within 24 months of first-line chemoimmunotherapy, this regimen...
Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ferdinandos Skoulidis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss results of a biomarker subgroup analysis, showing that sotorasib demonstrated consistent clinical benefit vs docetaxel in all molecularly defined...
Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
The use of preoperative magnetic resonance imaging (MRI) did not significantly reduce positive margins after breast-conserving surgery, according to data presented during a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Although MRI has been shown to detect...
New Data May Inform Treatment of Pregnant Patients With Relapsed or Refractory Lymphoma
In a new study reported by Farooq et al in Blood Advances, patients with relapsed or refractory lymphoma during pregnancy had a progression-free survival rate of 24% and an overall survival rate of 83%. Background Receiving a lymphoma diagnosis during pregnancy may be uncommon but can occur for...
Patients With Lymphoma Who Have Depression or Anxiety May Experience Worse Survival Outcomes
Investigators have found that patients who had depression and/or anxiety prior to their diagnosis of diffuse large B-cell lymphoma (DLBCL) may have had shorter survival times than patients who didn’t have a mental health condition prior to their DLBCL diagnosis, according to a new study published...
NCI’s ComboMATCH Initiative Will Evaluate New Drug Combinations Guided by Tumor Biology
The National Cancer Institute (NCI) has launched a new set of large, precision medicine–based clinical trials—known as the ComboMATCH initiative—that will examine the efficacy of novel drug combinations targeting specific tumor mutations in adult and pediatric patients with cancer. The new...
Early Detection of Pancreatic Cancer Saved My Life
When my sister was diagnosed with breast cancer 25 years ago, her medical team suggested we undergo genetic testing for the BRCA gene mutation. I knew that being a BRCA carrier put me at greater risk for breast and ovarian cancers, but I had no idea it also increased my risk for pancreatic cancer....
Tak W. Mak, PhD, FAACR, Selected for 2023 Pezcoller Foundation–AACR International Award for Achievement in Cancer Research
Tak W. Mak, PhD, FAACR, was recently announced as this year’s winner of the Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research. Dr. Mak is Senior Scientist at the Princess Margaret Cancer Centre, University...
Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib
Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA...
Rethinking Prior Authorization
Prior authorization of medical procedures, services, and medications has been a standard requirement of health-care providers for decades. Rising health-care costs, specifically the escalating prices of cancer drug therapies, have led to a new focus by payers, providers, and policymakers on prior...
Reducing Air Pollution Globally May Contribute to Healthier Lifestyles and Lower Cancer Risks
The Union for International Cancer Control (UICC) has called for global action to improve public health and prevent millions of deaths from cancer and other noncommunicable diseases by drastically reducing air pollution in light of World Environment Day on June 5, 2023. "Creating cleaner and...
Cancer Survivors Who Quit Smoking May Have 36% Lower Cardiovascular Risk Than Those Who Continue Smoking
Patients who continue smoking after a cancer diagnosis may have almost a twofold risk of experiencing a heart attack, stroke, or death as a result of cardiovascular disease compared with nonsmokers, according to a new study published by Lee et al in the European Heart Journal. Background According...
NCCN Addresses Ongoing Chemotherapy Shortages as New Survey Suggests More than 90% of Cancer Centers May Be Impacted
Results of a new survey from the National Comprehensive Cancer Network (NCCN) have shed light on the widespread impact of the current carboplatin and cisplatin shortages. In a separate statement, the NCCN called on the whole oncology community to work together on solutions. Background Carboplatin...
Involving All of Society to End Cancer as We Know It
This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months...
Second-Generation Antiandrogens and Cognitive and Functional Toxicity in Patients With Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Nowakowska et al found that use of second-generation antiandrogens for the treatment of prostate cancer was associated with increased risk of cognitive toxicity, fatigue, and falls in patients. Study Details The analysis included...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Cancer Center, University of Miami, said the COMMANDS trial delivered promising results for the treatment of lower-risk myelodysplastic syndrome (MDS). “Without question, the COMMANDS study met its...
Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by...
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with...
Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat...
Black and Hispanic Cancer Survivors May Have Highest Risk of Death From Subsequent Primary Cancers and Cardiovascular Disease
Black and Hispanic cancer survivors with subsequent primary malignancies may have a higher risk of mortality compared with White patients, according to new findings presented by Sung et al at the 2023 ASCO Annual Meeting (Abstract 12093). The new research demonstrated that Black patients with...
Cancer Survivors With Transportation Barriers to Care May Also Experience Financial Hardship, Food Insecurity, and Delays in Timely Care
Investigators have found that many U.S. cancer survivors with transportation barriers to care also reported struggling financially and experiencing additional barriers to timely care, according to new findings presented by Jiang et al at the 2023 ASCO Annual Meeting (Abstract 6534). Study Methods...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal cancer,...
Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care ...
Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy
Tycel J. Phillips, MD, of City of Hope National Medical Center, and Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and the International Extranodal Lymphoma Study Group, discuss findings from the largest prospective study of patients with primary mediastinal B-cell lymphoma....
James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab
James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital and National Taiwan University Cancer Center, discusses the latest data from the phase III KEYNOTE-789 study, which evaluated the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or ...
Radiation Treatment May Not Be Necessary After Chemoimmunotherapy for Primary Mediastinal B-Cell Lymphoma
Results from the largest prospective study of patients with primary mediastinal B-cell lymphoma (PMBCL) showed that radiation therapy may be omitted in patients who have a complete metabolic response after chemoimmunotherapy. The IELSG37 international study found that these patients may be spared...
Stopping Immunotherapy After 2 Years vs Continuing Treatment May Yield Similar Survival Outcomes in Patients With Advanced NSCLC
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Race and Ethnicity May Affect 21-Gene Recurrence Score in Patients With Estrogen Receptor–Positive Breast Cancer
Investigators have found that race and ethnicity may affect the 21-gene recurrence score in patients with early-stage, estrogen receptor–positive breast cancer, according to new findings presented by Gill et al at the 2023 ASCO Annual Meeting (Abstract 511). Background The 21-gene recurrence...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Erdafitinib Achieves Responses Across Multiple Cancer Types With FGFR Alterations
Three clinical trials demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations. The data were presented at the 2023 ASCO Annual Meeting. Erdafitinib is an oral medication that blocks the activity of FGFR signaling...
Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax
Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Zeynep Eroglu, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses phase II findings showing that in patients with BRAF-mutant metastatic melanoma, dabrafenib plus trametinib and navitoclax (DTN) was...
